CCM
RARE icon

Catalio Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Catalio Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6M Sell
316,252
-534,545
-63% -$13.3M 1.98% 20
2026
Q1 		$17.8M Buy
850,797
+688,247
+423% +$15.5M 3.72% 11
2025
Q4 		$3.74M Sell
162,550
-128,712
-44% -$4.23M 0.66% 33
2025
Q3 		$8.76M Buy
291,262
+77,860
+36% +$2.33M 1.62% 23
2025
Q2 		$7.76M Buy
+213,402
New +$7.69M 1.63% 19

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Catalio Capital Management's RARE Position: Q2 2026 in Review

Catalio Capital Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 63% in Q2 2026, selling an estimated $13.3M and leaving 316,252 shares worth $10.6M. The position accounts for 1.98% of the portfolio, ranked #20.

Catalio Capital Management first reported a position in RARE in Q2 2025 and has held it in 5 quarters since. The position peaked at $17.8M in Q1 2026. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Catalio Capital Management held 316,252 shares of Ultragenyx Pharmaceutical worth $10.6M as of Q2 2026.
  • Catalio Capital Management sold 534,545 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $13.3M.
  • Ultragenyx Pharmaceutical made up 1.98% of Catalio Capital Management's portfolio in Q2 2026, its #20 holding.
  • Catalio Capital Management first reported a position in Ultragenyx Pharmaceutical in Q2 2025 and has held it in 5 quarters since.
  • Catalio Capital Management's Ultragenyx Pharmaceutical position peaked at $17.8M in Q1 2026.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.